Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:53 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1873–1896 of 3,759 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Phase duration Clear all

Conditions: Hyponatremia
Interventions: Tolvaptan; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 4 Years to 18 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Aurora, Colorado • Washington D.C., District of Columbia • Atlanta, Georgia + 8 more

Conditions: Breast Cancer
Interventions: Breast MRI, Breast-Q© questionnaire, Multi-Beam IMRT; Device · Behavioral · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 4 more

Conditions: PreDiabetes
Interventions: Standard NDPP, Very low-carbohydrate diet; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Insomnia, Depression
Interventions: Cognitive Behavioral Therapy for Insomnia; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Chronobiology, Light, Sleep, Circadian Rhythm, Adolescence
Interventions: Baseline Sleep Satiation and Phase Stabilization, Gradually Shifted Sleep; Behavioral
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 20 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
Interventions: ATLCAR.CD30 cells; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 3 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2037
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Liver Cancer
Interventions: doxorubicin hydrochloride, mitomycin C, sorafenib tosylate, laboratory biomarker analysis, pharmacological study; Drug · Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Carotid Artery Diseases, Aortic Diseases, Peripheral Arterial Diseases
Interventions: Intergard Standard - Collagen Coated Vascular Grafts and Patches, Hemashield - Collagen Coated Vascular Grafts and Patches, Intergard Silver - Antimicrobial Collagen Coated Vascular Grafts and Patches, Intergard Synergy - Antimicrobial Collagen Coated Vascular Grafts; Device
Lead sponsor: Intervascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Hershey, Pennsylvania • Pittsburgh, Pennsylvania

Conditions: Infertility, Pregnancy
Interventions: Crinone vaginal progesterone gel, Placebo vaginal gel; Drug
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Mild Cognitive Impairment
Interventions: Time-restricted eating; Behavioral
Lead sponsor: Julie Pendergast; Other
Eligibility: 45 Years to 95 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Metastatic Neuroendocrine Prostate Cancer
Interventions: [68Ga]Ga-PSMA-11, [68Ga]GA-DOTA-TATE, [68Ga]Ga-NeoB, [177Lu]Lu-PSMA-617, [177Lu]Lu-DOTA-TATE, [177Lu]Lu-NeoB, L-Lysine HCl-L-Arginine HCl, 2.5 %,, Gonadotropin-releasing hormone (GnRH) analogues, GnRH antagonists, Antiemetics & antinauseants, Metoclopramide; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 2
States / cities: Omaha, Nebraska • New York, New York

Conditions: Chronic Myelogenous Leukemia
Interventions: imatinib mesilate, interferon-alpha (INF-a), cytarabine (ARA-C); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 1,106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2012
U.S. locations: 62
States / cities: Birmingham, Alabama • Montgomery, Alabama • Tucson, Arizona + 50 more

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: lintuzumab, 5-azacytidine; Biological · Drug
Lead sponsor: Alison Walker; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Solid Tumors
Interventions: ABBV-303, Budigalimab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 11
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 7 more

Conditions: Hypoglycemia, Reactive, Hypoglycemia
Interventions: Dexcom CGM masked, Dexcom CGM unmasked; Device
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, High Grade Ovarian Serous
Interventions: PET/MRI, Contrast enhanced CT; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Headache, Migraine, Multiple Sclerosis
Interventions: RELAXaHEAD app, Monitored Usual Care (MUC); Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Lymphocytic Leukemia
Interventions: Ofatumumab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Critical Illness
Interventions: PICU Up!; Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 0 Years to 24 Years
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: intoplicine; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1997
U.S. locations: 2
States / cities: Fort Sam Houston, Texas • San Antonio, Texas

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma, Pancreatic Carcinoma, Pancreatic Carcinoma Metastatic, Pancreatic Carcinoma Non-resectable, Pancreatic Cancer, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions: Pertzye; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma, Clear Cell Renal Cell Carcinoma Metastatic, Clear Cell Renal Cancer, Bone Metastases of a Malignant Tumor, Clear Cell Renal Cell Carcinoma, Bone, Metastatic Cancer, Metastatic Cancer, Metastatic Renal Cell Carcinoma, Metastases to Bone
Interventions: Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT), Bone Scan, Computerized tomography (CT) Scan; Drug · Radiation · Procedure
Lead sponsor: Kelly Fitzgerald, MD; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Acral Melanoma, Advanced Cutaneous Melanoma, Advanced Mucosal Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Acral Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Mucosal Melanoma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Medical Device Usage and Evaluation, Nivolumab, Questionnaire Administration; Procedure · Biological · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Esophagus Cancer, Esophageal Cancer, Cancer of the Esophagus
Interventions: Proton beam therapy, Patient-Reported Outcome Measures; Radiation · Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Search by objective public record fields.

An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia

Study Assessing the Potential for Reduced Rates of Implant Failure Using Multi-Beam Intensity-Modulated Radiation Therapy for Locally Advanced Breast Cancer Patients With Implant Reconstructions

The Lifestyle Education About Prediabetes (Leap) Study

Sleep Mechanisms Of Regulating Emotions

Light Timing Study

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

Intervascular Post-Market Clinical Follow-Up (PMCF) Registry

Sexual Absorption of Vaginal Progesterone

Feasibility of Implementing Time-restricted Eating in Women With Mild Cognitive Impairment

NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia

Azacitidine and Lintuzumab in Treating Patients With Previously Untreated Myelodysplastic Syndromes

A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors

Continuous Glucose Monitoring to Reduce Hypoglycemia and Improve Safety After Gastric Surgery

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

RELAXaHEAD for Headache Patients (Phase I)

Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

PICU Up!: A Pilot Stepped-wedge Trial of a Multicomponent Early Mobility Intervention for Critically Ill Children

Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)

Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases

Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial

Proton Beam Therapy in the Treatment of Esophageal Cancer